Eric Allémann

University of Geneva
Country flagSwitzerland

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

The injectability of cross-linked hyaluronic acid (HA) dermal fillers is influenced by polymer concentration, polymer cross-linking type and degree, the presence of lidocaine or other functional excipients, types of syringes, and injection techniques. Finished product injectability constitutes a critical quality attribute for clinical injectors, as it strongly influences product applicability and ease of use in aesthetic medicine. While injectable product extrusion force specifications are provided by the respective device manufacturers, the qualitative informative value of such datasets is low for injectors wishing to compare product brands and technologies from an injectability standpoint. Therefore, the present study comparatively assessed 28 cross-linked HA dermal fillers (JUVÉDERM®, Restylane®, BELOTERO®, TEOSYAL RHA®, and STYLAGE® brands) using various injectability benchmarking setups for enhanced clinical-oriented relevance. Manual product injections were performed by three specialized and experienced clinicians, whereas automatic product extrusion was performed using a Texture Analyzer instrument. The various hydrogel products were injected into ex vivo human skin and into SimSkin® cutaneous equivalents to appropriately account for injection-related counterpressure. The injectability results revealed important variability between and within product brands, with a strong influence of the local anesthetic lidocaine, HA contents, and needle gauge size. Critical appraisals of the investigated products were performed, notably from manufacturing process-based and clinical ease of application-based standpoints, centered on respective experimental injectability quality levels. Generally, it was confirmed that each HA-based dermal filler product requires specific expertise for optimal injection, mainly due to differing viscoelastic characteristics and injectability attributes. Overall, the present study set forth evidence-based and clinical-oriented rationale elements confirming the importance for injectors to work with injectable products with which they are experienced and comfortable to optimize clinical results.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Collaborators (12)

wassim raffoul

Head of Department

Lausanne University Hospital

SWITZERLAND
View details

Maria Isabel Vargas

Prof. Dr

Hôpitaux Universitaires Genève

SWITZERLAND
View details

Benoit Guery

Associate Professor

Lausanne University Hospital

SWITZERLAND
View details

Philippe Bijlenga

Professeur associé

Université Grenoble Alpes Faculté de Médecine

SWITZERLAND
View details

Olivier Jordan

University of Geneva

SWITZERLAND
View details

François Graham

Geneva University Hospitals (HUG)

SWITZERLAND
View details

Emerson Ferreira Queiroz

Senior lecturer/Maître d'enseignement et de recherche

Université de Genève

SWITZERLAND
View details

Florence Delie

University of Geneva

SWITZERLAND
View details

Lee Ann Applegate

Lausanne University Hospital

SWITZERLAND
View details

Anthony de Buys Roessingh

Lausanne University Hospital

SWITZERLAND
View details

Brenda Kwak

Full professor

University of Geneva

SWITZERLAND
View details

Yogeshvar Kalia

Full Professor (Medicinal/Pharmaceutical Chemistry)

University of Geneva

SWITZERLAND
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.